Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

HPV Vaccination: Prevention of Cervical Cancer in Serbia and in Europe

HPV Vaccination: Prevention of Cervical Cancer in Serbia and in Europe References1. zur Hausen H. The search for infectious causes of human cancers: Where and why (Nobel Lecture). Virology 2009;48(32):1–10. https://doi.org/10.1016/j.virol.2009.06.0012. Bautista OM, Luxembourg A. Deconstructing the measure of vaccine efficacy against disease irrespective of HPV in HPV vaccine clinical trials. Contemp Clin Trials 2016;47:254–8. https://doi.org/10.1016/j.cct.2016.01.0023. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136(5):E359–86. https://doi.org/10.1002/ijc.292104. Bruni L, Barrionuevo-Rosas L, Albero G, Aldea M, Serrano B, Valencia S, Brotons M, Mena M C, R, Muoz J, Bosch FX, de Sanjosé S. CXIIC on H and C (HPV, Report ICHP and RD in ZS, Accessed) 2016-02-26. [Data. Human Papillomavirus and Related Diseases Report/Serbia [Internet]. Bruni L, Barrionuevo-Rosas L, Albero G, Aldea M, Serrano B, Valencia S, Brotons M, Mena M, Cosano R, Muoz J, Bosch FX, de Sanjosé S, Castellsagué X. ICO Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Disease. 2016 [accessed 2017 Feb 7]. www.hpvcentre.com5. Pratt JL, zur Hausen H. Papillomaviruses in the causation of human cancers - a brief historical account. Virology 2009;384(2):260–5. https://doi.org/10.1016/j.virol.2008.11.0466. zur Hausen H. Condylomata Acuminata and Human Genital Cancer. Cancer Res 1974;36:794. http://cancerres.aacrjournals.org/content/36/2_Part_2/794.long7. Calkins H, zur Hausen H. Oncogenic herpes viruses. Biochim. Biophys Acta 1975; 417(1):25–53. https://doi.org/10.1016/0304-419X(75)90007-48. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev 2002;2(5):342–50. https://doi.org/10.1038/nrc7989. Dürst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A. 1983;80(12):3812–5. https://doi.org/10.1073/pnas.80.12.381210. Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W, zur Hausen H. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J 1984;3(5):1151–7. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=557488&tool=pmcentrez&rendertype=abstract11. Wolff GS Verissimo J, de Medeiros Fernandes TAA. Human Papillomavirus: Biology and Pathogenesis. In: Broeck DV (ed), Human Papillomavirus and Related Diseases - From Bench to Bedside - A Clinical Perspective. ISBN 978-953-307-860-1, InTech, 2012: 3–40. https://doi.org/10.5772/2715412. Oliveira C. Low and High-Oncogenic Risk Human Papillomaviruses: Every Rule Has its Exception. J Bras Doenças. Sex Transm 2011;23(4):174–6. http://www.dst.uff.br/revista23-4-2011/3.EDITORIAL-INGLES.pdf%5Cn http://www.dst.uff.br//revista23-4-2011/3.EDITORIAL-INGLES.pdf13. Johnsrude CL. De Villiers EM, Fauquet C, Broker TR, Bernard HU, Zur Hausen H. Classification of papillomaviruses. Virology 2004;324(1):17–27. https://doi.org/10.1016/j.virol.2004.03.03314. Villain E. Woodman C, Collins S, Young C, Young LS. The natural history of cervical HPV infection: unresolved issues - ProQuest. Nat Rev Cancer 2007;7:11–22. https://doi.org/10.1038/nrc205015. No Title [Internet]. 2008 [accessed 2017 Feb 2]. https://www.nobelprize.org/nobel_prizes/medicine/laureates/2008/press.pdf16. Anderson MC, Brown CL, Buckley CH, Fox H, Jenkins D, Lowe DG, et al. Current views on cervical intraepithelial neoplasia. J Clin Pathol 1991;44:969–78. https://doi.org/10.1136/jcp.44.12.96917. Luyten A, Buttmann-Schweiger N, Luyten K, Mauritz C, Reinecke-Lüthge A, Pietralla M, et al. Early detection of CIN3 and cervical cancer during long-term follow-up using HPV/Pap smear co-testing and risk-adapted follow-up in a locally organised screening programme. Int J Cancer 2014;135(6):1408–16.https://doi.org/10.1002/ijc.2878318. Yaqub O, Castle-Clarke S, Sevdalis N, Chataway J. Attitudes to vaccination: A critical review. Soc Sci Med 2014;112:1–11. https://doi.org/10.1016/j.socscimed.2014.04.01819. Walboomers JMM, Jacobs M V., Manos MM, Bosch FX, Kummer JA, Shah K V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189(1):12–9. https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F20. Schiller JT, Davies P. Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol 2004;2(4):343–7. https://doi.org/10.1038/nrmicro86721. Kirnbauer R, Booyt F, Chengt N, Lowy DR, Schiller JT. Papillomavirus Li major capsid protein self-assembles into virus-like particles that are highly immunogenic. Med Sci 1992;89 (24):12180–4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC50722/pdf/pnas01098-0541.pdf22. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991;185(1):251–7. https://doi.org/10.1016/0042-6822(91)90772-423. Suzich JA, Ghimtt S-J, Palmer-Hill FJ, White WI, Tamura JK, Belli JA, et al. Systemic immunization with papillomavirus Li protein completely prevents the development of viral mucosal papillomas. Immunology 1995;92:11553–7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC40440/pdf/pnas01503-0241.pdf24. Huber B, Schellenbacher C, Shafti-Keramat S, Jindra C, Christensen N, Kirnbauer R. Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV). PLoS One 2017;12(1):e0169533. https://doi.org/10.1371/journal.pone.016953325. Angioli R, Lopez S, Aloisi A, Terranova C, De Cicco C, Scaletta G, et al. Ten years of HPV vaccines: State of art and controversies. Crit Rev Oncol Hematol 2016;102:65–72. https://doi.org/10.1016/j.critrevonc.2016.03.02026. Audisio RA, Icardi G, Isidori AM, Liverani CA, Lombardi A, Mariani L, et al. Public health value of universal HPV vaccination. Crit Rev Oncol Hematol 2016;97:157–67. https://doi.org/10.1016/j.critrevonc.2015.07.01527. Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012;30(5):F123-138. https://doi.org/10.1016/j.vaccine.2012.04.10828. Castellsagué X, Schneider A, Kaufmann AM, Bosch FX. HPV vaccination against cervical cancer in women above 25 years of age: Key considerations and current perspectives. Gynecol Oncol 2009; 115(3):S15–23. https://doi.org/10.1016/j.ygyno.2009.09.02129. Chandler RE, Juhlin K, Fransson J, Caster O, Edwards IR, Norén GN. Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase®. Drug Saf 2016;1–10. https://doi:10.1007/s40264-016-0456-330. Kreimer AR, Gonzalèz P, Katki HA, Porras C, Schiffman M, Rodriguez AC, et al. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol 2011;12(9):862–70. https://doi.org/10.1016/S1470-2045(11)70213-331. Talebi S, Bolhassani A, Sadat SM, Vahabpour R, Agi E, Shahbazi S. Hp91 immunoadjuvant: An HMGB1-derived peptide for development of therapeutic HPV vaccines. Biomed Pharmacother. 2017;85:148–54. https://doi.org/10.1016/j.biopha.2016.11.11532. Tota JE, Ramanakumar A V, Jiang M, Dillner J, Walter SD, Kaufman JS, et al. Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination. Am J Epidemiol 2013;178(4):625–34. https://doi.org/10.1093/aje/kwt01833. Roden R and Wu TC.. How will HPV vaccines affect cervical cancer? Nat Rev Cancer 2006;6(10):753–63. https://doi.org/10.1038/nrc197334. Kim KS, Park SA, Ko K-N, Yi S, Cho YJ. Current status of human papillomavirus vaccines. Clin Exp Vaccine Res 2014;3(2):168–75. https://doi.org/10.7774/cevr.2014.3.2.16835. Herrero R, Gonzalez P, Markowitz LE. Present status of human papillomavirus vaccine development and implementation. Lancet Oncol 2015;16 (5): e206–16. https://doi.org/10.1016/S1470-2045(14)70481-436. Poethko-Müller C, Buttmann-Schweiger N. Impf-status und Determinanten der Impfung gegen humane Papillomviren (HPV) bei Mädchen in Deutschland: Ergebnisse der KiGGS-Studie - Erste Folgebefragung (KiGGS Welle 1). Bundesgesund-heitsblatt - Gesundheitsforsch - Gesundheitsschutz. [German] 2014;57(7):869–77.37. Rieck T, Fachgebiet Impfprävention der Abteilung für Infektionsepidemiologie des RKI. Impfquoten der Masern-, HPV- und Influenza-Impfung in Deutschland. Epidemiol Bull 2016; (1):1–10. https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2016/Ausgaben/01_16.pdf?__blob=publicationFile38. Institut Català d'Oncologia (ICO). Human Papillomavirus and Related Diseases Report. HPV Information Centre. 2016 [accessed 2017 Feb 7]. http://www.hpvcentre.net/statistics/reports/COL.pdf39. Haverkate M, D'Ancona F, Giambi C, Johansen K, Lopalco PL, Cozza V, et al. Mandatory and recommended vaccination in the EU, Iceland and Norway: Results of the VENICE 2010 survey on the ways of implementing national vaccination programmes. Eurosurveillance 2012;17(22):1–6. https://doi.org/10.2807/ese.17.22.20183-en40. ХПВ вакцина [accessed 2014 Feb 6]. http://www.batut.org.rs/download/aktuelno/2016BrosuraHPV.pdf http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Facultatis Medicae Naissensis de Gruyter

HPV Vaccination: Prevention of Cervical Cancer in Serbia and in Europe

Loading next page...
 
/lp/de-gruyter/hpv-vaccination-prevention-of-cervical-cancer-in-serbia-and-in-europe-D005K79rr9
Publisher
de Gruyter
Copyright
© 2018 Holger Stark et al., published by De Gruyter Open
ISSN
2217-2521
eISSN
2217-2521
DOI
10.2478/afmnai-2018-0001
Publisher site
See Article on Publisher Site

Abstract

References1. zur Hausen H. The search for infectious causes of human cancers: Where and why (Nobel Lecture). Virology 2009;48(32):1–10. https://doi.org/10.1016/j.virol.2009.06.0012. Bautista OM, Luxembourg A. Deconstructing the measure of vaccine efficacy against disease irrespective of HPV in HPV vaccine clinical trials. Contemp Clin Trials 2016;47:254–8. https://doi.org/10.1016/j.cct.2016.01.0023. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136(5):E359–86. https://doi.org/10.1002/ijc.292104. Bruni L, Barrionuevo-Rosas L, Albero G, Aldea M, Serrano B, Valencia S, Brotons M, Mena M C, R, Muoz J, Bosch FX, de Sanjosé S. CXIIC on H and C (HPV, Report ICHP and RD in ZS, Accessed) 2016-02-26. [Data. Human Papillomavirus and Related Diseases Report/Serbia [Internet]. Bruni L, Barrionuevo-Rosas L, Albero G, Aldea M, Serrano B, Valencia S, Brotons M, Mena M, Cosano R, Muoz J, Bosch FX, de Sanjosé S, Castellsagué X. ICO Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Disease. 2016 [accessed 2017 Feb 7]. www.hpvcentre.com5. Pratt JL, zur Hausen H. Papillomaviruses in the causation of human cancers - a brief historical account. Virology 2009;384(2):260–5. https://doi.org/10.1016/j.virol.2008.11.0466. zur Hausen H. Condylomata Acuminata and Human Genital Cancer. Cancer Res 1974;36:794. http://cancerres.aacrjournals.org/content/36/2_Part_2/794.long7. Calkins H, zur Hausen H. Oncogenic herpes viruses. Biochim. Biophys Acta 1975; 417(1):25–53. https://doi.org/10.1016/0304-419X(75)90007-48. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev 2002;2(5):342–50. https://doi.org/10.1038/nrc7989. Dürst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A. 1983;80(12):3812–5. https://doi.org/10.1073/pnas.80.12.381210. Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W, zur Hausen H. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J 1984;3(5):1151–7. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=557488&tool=pmcentrez&rendertype=abstract11. Wolff GS Verissimo J, de Medeiros Fernandes TAA. Human Papillomavirus: Biology and Pathogenesis. In: Broeck DV (ed), Human Papillomavirus and Related Diseases - From Bench to Bedside - A Clinical Perspective. ISBN 978-953-307-860-1, InTech, 2012: 3–40. https://doi.org/10.5772/2715412. Oliveira C. Low and High-Oncogenic Risk Human Papillomaviruses: Every Rule Has its Exception. J Bras Doenças. Sex Transm 2011;23(4):174–6. http://www.dst.uff.br/revista23-4-2011/3.EDITORIAL-INGLES.pdf%5Cn http://www.dst.uff.br//revista23-4-2011/3.EDITORIAL-INGLES.pdf13. Johnsrude CL. De Villiers EM, Fauquet C, Broker TR, Bernard HU, Zur Hausen H. Classification of papillomaviruses. Virology 2004;324(1):17–27. https://doi.org/10.1016/j.virol.2004.03.03314. Villain E. Woodman C, Collins S, Young C, Young LS. The natural history of cervical HPV infection: unresolved issues - ProQuest. Nat Rev Cancer 2007;7:11–22. https://doi.org/10.1038/nrc205015. No Title [Internet]. 2008 [accessed 2017 Feb 2]. https://www.nobelprize.org/nobel_prizes/medicine/laureates/2008/press.pdf16. Anderson MC, Brown CL, Buckley CH, Fox H, Jenkins D, Lowe DG, et al. Current views on cervical intraepithelial neoplasia. J Clin Pathol 1991;44:969–78. https://doi.org/10.1136/jcp.44.12.96917. Luyten A, Buttmann-Schweiger N, Luyten K, Mauritz C, Reinecke-Lüthge A, Pietralla M, et al. Early detection of CIN3 and cervical cancer during long-term follow-up using HPV/Pap smear co-testing and risk-adapted follow-up in a locally organised screening programme. Int J Cancer 2014;135(6):1408–16.https://doi.org/10.1002/ijc.2878318. Yaqub O, Castle-Clarke S, Sevdalis N, Chataway J. Attitudes to vaccination: A critical review. Soc Sci Med 2014;112:1–11. https://doi.org/10.1016/j.socscimed.2014.04.01819. Walboomers JMM, Jacobs M V., Manos MM, Bosch FX, Kummer JA, Shah K V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189(1):12–9. https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F20. Schiller JT, Davies P. Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol 2004;2(4):343–7. https://doi.org/10.1038/nrmicro86721. Kirnbauer R, Booyt F, Chengt N, Lowy DR, Schiller JT. Papillomavirus Li major capsid protein self-assembles into virus-like particles that are highly immunogenic. Med Sci 1992;89 (24):12180–4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC50722/pdf/pnas01098-0541.pdf22. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991;185(1):251–7. https://doi.org/10.1016/0042-6822(91)90772-423. Suzich JA, Ghimtt S-J, Palmer-Hill FJ, White WI, Tamura JK, Belli JA, et al. Systemic immunization with papillomavirus Li protein completely prevents the development of viral mucosal papillomas. Immunology 1995;92:11553–7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC40440/pdf/pnas01503-0241.pdf24. Huber B, Schellenbacher C, Shafti-Keramat S, Jindra C, Christensen N, Kirnbauer R. Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV). PLoS One 2017;12(1):e0169533. https://doi.org/10.1371/journal.pone.016953325. Angioli R, Lopez S, Aloisi A, Terranova C, De Cicco C, Scaletta G, et al. Ten years of HPV vaccines: State of art and controversies. Crit Rev Oncol Hematol 2016;102:65–72. https://doi.org/10.1016/j.critrevonc.2016.03.02026. Audisio RA, Icardi G, Isidori AM, Liverani CA, Lombardi A, Mariani L, et al. Public health value of universal HPV vaccination. Crit Rev Oncol Hematol 2016;97:157–67. https://doi.org/10.1016/j.critrevonc.2015.07.01527. Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012;30(5):F123-138. https://doi.org/10.1016/j.vaccine.2012.04.10828. Castellsagué X, Schneider A, Kaufmann AM, Bosch FX. HPV vaccination against cervical cancer in women above 25 years of age: Key considerations and current perspectives. Gynecol Oncol 2009; 115(3):S15–23. https://doi.org/10.1016/j.ygyno.2009.09.02129. Chandler RE, Juhlin K, Fransson J, Caster O, Edwards IR, Norén GN. Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase®. Drug Saf 2016;1–10. https://doi:10.1007/s40264-016-0456-330. Kreimer AR, Gonzalèz P, Katki HA, Porras C, Schiffman M, Rodriguez AC, et al. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol 2011;12(9):862–70. https://doi.org/10.1016/S1470-2045(11)70213-331. Talebi S, Bolhassani A, Sadat SM, Vahabpour R, Agi E, Shahbazi S. Hp91 immunoadjuvant: An HMGB1-derived peptide for development of therapeutic HPV vaccines. Biomed Pharmacother. 2017;85:148–54. https://doi.org/10.1016/j.biopha.2016.11.11532. Tota JE, Ramanakumar A V, Jiang M, Dillner J, Walter SD, Kaufman JS, et al. Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination. Am J Epidemiol 2013;178(4):625–34. https://doi.org/10.1093/aje/kwt01833. Roden R and Wu TC.. How will HPV vaccines affect cervical cancer? Nat Rev Cancer 2006;6(10):753–63. https://doi.org/10.1038/nrc197334. Kim KS, Park SA, Ko K-N, Yi S, Cho YJ. Current status of human papillomavirus vaccines. Clin Exp Vaccine Res 2014;3(2):168–75. https://doi.org/10.7774/cevr.2014.3.2.16835. Herrero R, Gonzalez P, Markowitz LE. Present status of human papillomavirus vaccine development and implementation. Lancet Oncol 2015;16 (5): e206–16. https://doi.org/10.1016/S1470-2045(14)70481-436. Poethko-Müller C, Buttmann-Schweiger N. Impf-status und Determinanten der Impfung gegen humane Papillomviren (HPV) bei Mädchen in Deutschland: Ergebnisse der KiGGS-Studie - Erste Folgebefragung (KiGGS Welle 1). Bundesgesund-heitsblatt - Gesundheitsforsch - Gesundheitsschutz. [German] 2014;57(7):869–77.37. Rieck T, Fachgebiet Impfprävention der Abteilung für Infektionsepidemiologie des RKI. Impfquoten der Masern-, HPV- und Influenza-Impfung in Deutschland. Epidemiol Bull 2016; (1):1–10. https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2016/Ausgaben/01_16.pdf?__blob=publicationFile38. Institut Català d'Oncologia (ICO). Human Papillomavirus and Related Diseases Report. HPV Information Centre. 2016 [accessed 2017 Feb 7]. http://www.hpvcentre.net/statistics/reports/COL.pdf39. Haverkate M, D'Ancona F, Giambi C, Johansen K, Lopalco PL, Cozza V, et al. Mandatory and recommended vaccination in the EU, Iceland and Norway: Results of the VENICE 2010 survey on the ways of implementing national vaccination programmes. Eurosurveillance 2012;17(22):1–6. https://doi.org/10.2807/ese.17.22.20183-en40. ХПВ вакцина [accessed 2014 Feb 6]. http://www.batut.org.rs/download/aktuelno/2016BrosuraHPV.pdf

Journal

Acta Facultatis Medicae Naissensisde Gruyter

Published: Mar 1, 2018

There are no references for this article.